Share/Bookmark

New Drugs for Juvenile Myositis

Virtual Symposium featuring speakers from pharma and biotech, research hospitals and the NIH
October 17 from 11:00am - 3:00pm EST

 REGISTER NOW 

Proudly presented by Cure JM Foundation and Duke University Cure JM Center of Excellence

Cure JM Logo

 

Duke Children’s


Symposium focus:

New drugs for Juvenile Myositis (JM), including drugs that are actively being repurposed from other indications and new drugs that are not yet registered for any disease.

Sessions cover:

An overview of the biology, genomics and genetics associated with JM, highlighting potential pathways that could be targeted for therapeutic intervention. A range of drugs that are in clinical trials or planned to enter clinical trials in JM patients, discussing their target pathway and potential in treating JM patients.

Target audience:

Rheumatologists, pediatric and adult, rheumatology fellows, residents looking at rheumatology fellowships, the drug research community, in particular autoimmune drug discovery/translation groups, clinicians/physicians with an interest in pediatrics/rheumatological disease.

CME Credits:

This symposium has been accredited for up to 2.5 AMA PRA Category 1 credit(s)TM. Only sessions 1 and 2 are CME credit eligible. For more information, or to apply for credits, contact .

Session 1 Chair (11:00am - 1:00pm):

Robert A. Colbert, MD, PhD, Clinical Director and Chief of Pediatric Translational Research Branch, NIAMS/NIH.

Session 2 and 3 Chair (1:00pm - 3:00pm):

Ann M. Reed, MD, Chair, Department of Pediatrics, Duke University School of Medicine.

Agenda:

Session 1 (CME eligible)
11:00 - 11:10 Opening comments and introduction. Andrew Heaton, PhD (CSO, Cure JM Foundation)
11:10 - 11:35 Introduction to biology and potential druggable targeting JM treatment. Jeffrey Dvergsten, MD (Duke University, Duke Children’s Health Center)
11:35 - 12:00 Introduction to the JAK/STAT pathway, a key druggable target for the treatment of JM. John O’Shea, MD (NIAMS/NIH)
12:00 - 12:25 Baricitinib in refractory JM patients. Hanna Kim, MD, MS (NIAMS/NIH)
12:25 - 12:50 SOCS1 mimetic peptide as novel JAK inhibitor for potential treatment of JM. Charlly Kao, PhD (Center for Applied Genomics, Children’s Hospital of Philadelphia)
Session 2 (CME eligible)
1:00 - 1:25 Calcinosis in JM, its treatment and the use of sodium thiosulfate in its management. Adam Schiffenbauer, MD (NIEHS/NIH)
1:25 - 1:50 Abataceptin refractory JM. Rodolfo Curiel, MD, FACP, FACR (Medical Faculty Associates, The George Washington University)
1:50 - 2:15 Closing remarks. Kaveh Ardalan, MD (Duke University, Duke Children’s Health Center)
Session 3 (Non-CME Industry Section)
2:15 - 2:40 Development of vamorolone as a less toxic anti-inflammatory steroid. Eric Hoffman, PhD (VP of Research, ReveraGen)
2:40 - 2:50 The biology of ECS and CB2 agonism as a potential target for DM and other autoimmune diseases. Quin Dinh, MD (VP Head of Medical Affairs, Corbus Pharmaceuticals)

Duke Health Logo

In support of improving patient care, the Duke University Health System Department of Clinical Education and Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the health care team.

 

Jointly Accredited Provider logo

Category 1: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurse CE: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 2.5 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Other health professionals will receive 2.5and a certificate of attendance from an AMA PRA Category 1 Creditâ„¢ activity. License requirements are subject to change. It is recommended that participants contact their licensing boards for specific questions

VIEW / PRINT / DOWNLOAD A FLYER